Department of Pathology, University of Maryland School of Medicine, Baltimore, MD 21201-1192, USA.
Department of Medicine, University of Maryland School of Medicine, Baltimore, MD 21201-1192, USA.
Curr Oncol. 2024 Oct 2;31(10):5949-5959. doi: 10.3390/curroncol31100444.
This study aimed to evaluate if integrating diverse molecular biomarkers in plasma and sputum could improve the diagnosis of lung cancer. The study analyzed miRNAs in plasma and bacterial DNA in sputum from 58 lung cancer patients and 62 cancer-free smokers using droplet digital PCR. The individual plasma miRNA and sputum bacterial biomarkers had sensitivities of 62-71% and specificities of 61-79% for diagnosing lung cancer. A panel of plasma miRNA or sputum bacterial biomarkers produced sensitivities of 79-85% and specificities of 74-82%. An integromic signature consisting of two miRNAs in plasma and three bacterial biomarkers in sputum had a higher sensitivity (87%) and specificity (89%) compared to individual biomarkers. The signature's diagnostic value was confirmed in a validation cohort of 56 lung cancer patients and 59 controls, independent of tumor stage, histological type, and demographic factors. Integrating diverse molecular biomarkers in plasma and sputum could improve the diagnosis of lung cancer.
本研究旨在评估整合血浆和痰液中的多种分子生物标志物是否可以提高肺癌的诊断率。该研究使用液滴数字 PCR 分析了 58 名肺癌患者和 62 名非癌症吸烟者的血浆中的 microRNA 和痰液中的细菌 DNA。个体血浆 microRNA 和痰液细菌生物标志物对诊断肺癌的敏感性为 62-71%，特异性为 61-79%。一组血浆 microRNA 或痰液细菌生物标志物的敏感性为 79-85%，特异性为 74-82%。由血浆中的两个 microRNA 和痰液中的三个细菌生物标志物组成的整合组学特征与单个生物标志物相比，具有更高的敏感性（87%）和特异性（89%）。该特征在 56 名肺癌患者和 59 名对照的验证队列中得到了确认，且与肿瘤分期、组织学类型和人口统计学因素无关。整合血浆和痰液中的多种分子生物标志物可以提高肺癌的诊断率。
